• In mid-March 2026, AXT Inc. reported that it had begun receiving export permits for indium phosphide substrates and outlined plans to double its manufacturing capacity this year to support growing AI infrastructure demand, even as earlier permit shortfalls had constrained fourth-quarter revenue.
• Alongside this upbeat operational update, significant insider share sales by CEO Morris Young and Director Jesse Chen added a contrasting governance angle for investors assessing the company’s trajectory.
• We’ll now examine how AXT’s plan to double indium phosphide capacity reshapes its existing investment narrative and risk-reward profile.

Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

AXT Investment Narrative Recap

To own AXT today, you have to believe that its indium phosphide business can translate rising AI infrastructure demand into sustainable revenue and margin improvement, while the company manages regulatory and concentration risks tied to China. The recent progress on export permits directly affects the key short term catalyst of converting backlog into sales, but the lingering risk is that permit approvals remain uneven and continue to cap how much of that demand AXT can actually serve.

The most relevant recent update is AXT’s Q4 2025 report, which showed a year over year revenue decline to US$23.04 million and a full year net loss of US$21.26 million, even as cash and cash equivalents increased. Against that backdrop, management’s plan to double indium phosphide capacity and its expectation for sequential Q1 revenue growth highlight how much of the near term thesis now hinges on converting AI driven orders into actual shipments without renewed export disruptions.

Yet investors should also be aware that persistent export permit uncertainty could still...

AXT's narrative projects $117.8 million revenue and $16.6 million earnings by 2028.

Uncover how AXT's forecasts yield a $28.25 fair value, a 42% downside to its current price.

Exploring Other Perspectives

Compared with the consensus story that leans on strong AI driven demand, the lowest analysts were assuming only about 11 percent annual revenue growth and no profitability within three years, so this new permit progress could either soften that pessimism or reinforce their concerns if approvals falter again.

Explore 4 other fair value estimates on AXT - why the stock might be worth as much as $30.75!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AXT research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free AXT research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AXT's overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• Find 49 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.